INTRODUCTION: Cancers of the pancreas are identified in 11 800 to 13 500 patients each year in Germany. Epidemiological studies prove smoking and chronic alcohol consumption as causes of about 30% of pancreatic cancers. METHODS: Selective literature review. RESULTS: Only patients within TNM stage I and II have after oncologic tumor extirpation a chance for long term survival. Controlled prospective clinical trials demonstrated adjuvant chemotherapy yielding an additional significant survival benefit. The 3- and 5-year-survival after R0-resection and adjuvant chemotherapy are about 30% and below 15% respectively. Using the criteria of observed 5-year-survival less than 2% of all pancreatic cancer patients are alive. After R0-resection the median survival time is between 17 and 28 months, after R1/2-resection between 8 and 22 months. DISCUSSION: Pancreatic cancer is even today for more than 95% of the patients incurable. Strategies to prevent pancreatic cancer are intended to stop smoking and chronic alcohol consumption and early surgical extirpation of cystic neoplastic lesions. For patients with established pancreatic cancer risk a follow-up protocol is discussed.
INTRODUCTION:Cancers of the pancreas are identified in 11 800 to 13 500 patients each year in Germany. Epidemiological studies prove smoking and chronic alcohol consumption as causes of about 30% of pancreatic cancers. METHODS: Selective literature review. RESULTS: Only patients within TNM stage I and II have after oncologic tumor extirpation a chance for long term survival. Controlled prospective clinical trials demonstrated adjuvant chemotherapy yielding an additional significant survival benefit. The 3- and 5-year-survival after R0-resection and adjuvant chemotherapy are about 30% and below 15% respectively. Using the criteria of observed 5-year-survival less than 2% of all pancreatic cancerpatients are alive. After R0-resection the median survival time is between 17 and 28 months, after R1/2-resection between 8 and 22 months. DISCUSSION: Pancreatic cancer is even today for more than 95% of the patients incurable. Strategies to prevent pancreatic cancer are intended to stop smoking and chronic alcohol consumption and early surgical extirpation of cystic neoplastic lesions. For patients with established pancreatic cancer risk a follow-up protocol is discussed.
Entities:
Keywords:
R0-resection; adjuvant chemotherapy; early cancer dissemination into nerves; lymph tissue and blood circulation; pancreatic cancer; systemic disease
Authors: Katherine R Birchard; Richard C Semelka; W Brian Hyslop; Alfonso Brown; Diane Armao; Zeynep Firat; Georgeta Vaidean Journal: AJR Am J Roentgenol Date: 2005-09 Impact factor: 3.959
Authors: Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess Journal: JAMA Date: 2007-01-17 Impact factor: 56.272
Authors: S Pedrazzoli; V DiCarlo; R Dionigi; F Mosca; P Pederzoli; C Pasquali; G Klöppel; K Dhaene; F Michelassi Journal: Ann Surg Date: 1998-10 Impact factor: 12.969
Authors: Philipp Horvath; Stefan Beckert; Florian Struller; Alfred Königsrainer; Marc André Reymond Journal: Clin Exp Metastasis Date: 2018-07-30 Impact factor: 5.150
Authors: Pratiek N Matkar; Eric D Jong; Ramya Ariyagunarajah; Gerald J Prud'homme; Krishna K Singh; Howard Leong-Poi Journal: Cancer Med Date: 2018-09-14 Impact factor: 4.452
Authors: Susanne Roth; Christoph Springfeld; Markus K Diener; Christine Tjaden; Phillip Knebel; Ulla Klaiber; Christoph W Michalski; Markus Mieth; Dirk Jäger; Markus W Büchler; Thilo Hackert Journal: BMJ Open Date: 2019-08-20 Impact factor: 2.692
Authors: Carolin Zimmermann; Gunnar Folprecht; Daniel Zips; Christian Pilarsky; Hans Detlev Saeger; Robert Grutzmann Journal: Cancers (Basel) Date: 2011-05-09 Impact factor: 6.639
Authors: Pratiek N Matkar; Krishna Kumar Singh; Dmitriy Rudenko; Yu Jin Kim; Michael A Kuliszewski; Gerald J Prud'homme; David W Hedley; Howard Leong-Poi Journal: Oncotarget Date: 2016-10-25